Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia.
Fukuchi
Kazuki
K
Department of Radiology, National Cardiovascular Center, Suita, Osaka, Japan. kfukuchi@hsp.ncvc.go.jp
Sasaki
Hideyuki
H
Yokoya
Takahiro
T
Noguchi
Teruo
T
Goto
Yoichi
Y
Hayashida
Kohei
K
Ishida
Yoshio
Y
D016477:Artifacts; D002951:Citrates / Q000493:pharmacokinetics; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D005708:Gallium / Q000493:pharmacokinetics; D006177:Gynecomastia / Q000139:chemically induced* / Q000000981:diagnostic imaging* / Q000378:metabolism; D006333:Heart Failure / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D008297:Male; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use
D002951:Citrates; D004232:Diuretics; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D013148:Spironolactone; D005708:Gallium; C103850:gallium citrate